Peter Verdult analyst CITI

Currently out of the existing stock ratings of Peter Verdult, 21 are a BUY (65.63%), 8 are a HOLD (25%), 3 are a SELL (9.38%).

Peter Verdult

Work Performance Price Targets & Ratings Chart

Analyst Peter Verdult, currently employed at CITI, carries an average stock price target met ratio of 37.5% that have a potential upside of 10.64% achieved within 144 days. Previously, Peter Verdult worked at BARCLAYS.

Peter Verdult’s has documented 52 price targets and ratings displayed on 7 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on LLY, Eli Lilly and Company at 12-Nov-2025.

Wall Street Analyst Peter Verdult

Analyst best performing recommendations are on NVO (NOVO NORDISK A/S).
The best stock recommendation documented was for NVO (NOVO NORDISK A/S) at 8/13/2025. The price target of $61 was fulfilled within 36 days with a profit of $10.67 (21.2%) receiving and performance score of 5.89.

Average potential price target upside

GLPG Galapagos NV ADR GRFS Grifols SA ADR NVO Novo Nordisk A/S EVO Evotec SE ADR GMAB Genmab AS SNY Sanofi ADR LLY Eli Lilly and Company

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 16-Oct-2020

$33

$4.87 (17.31%)

$32

Hold Since 09-Sep-2024

$40

$11.87 (42.20%)

$24

Hold Since 07-Mar-2024

$22

$-6.13 (-21.79%)

$31

Show more analysts

Please expand the browser size to see the chart

What Year was the first public recommendation made by Peter Verdult?

On 2016

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?